Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

How else can we approach prostate cancer biomarker discovery?

Drake RR, Angel PM, Wu J, Pachynski RK, Ippolito JE.

Expert Rev Mol Diagn. 2019 Sep 10:1-3. doi: 10.1080/14737159.2019.1665507. [Epub ahead of print] No abstract available.

PMID:
31498690
2.

Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.

Reimers MA, Slane KE, Pachynski RK.

Curr Urol Rep. 2019 Sep 3;20(10):64. doi: 10.1007/s11934-019-0931-3. Review.

PMID:
31482315
3.

Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.

Pachynski RK, Wang P, Salazar N, Zheng Y, Nease L, Rosalez J, Leong WI, Virdi G, Rennier K, Shin WJ, Nguyen V, Butcher EC, Zabel BA.

Front Immunol. 2019 May 8;10:983. doi: 10.3389/fimmu.2019.00983. eCollection 2019.

4.

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer.

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, Smith ZL, Andriole GL, Arora V, Bullock A, Carmona R, Figenshau RS, Grubb RL, Guzzo TJ, Knoche EM, Malkowicz SB, Mamtani R, Pachynski RK, Roth BJ, Zaghloul MS, Gay HA, Baumann BC.

Cancer Med. 2019 Jul;8(8):3698-3709. doi: 10.1002/cam4.2102. Epub 2019 May 22.

5.

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.

Fischer-Valuck BW, Michalski JM, Contreras JA, Brenneman R, Christodouleas JP, Abraham CD, Kim EH, Arora VK, Bullock AD, Carmona R, Figenshau RS, Grubb R 3rd, Knoche EM, Pachynski RK, Picus J, Roth BJ, Sargos P, Andriole GL, Gay HA, Baumann BC.

Clin Transl Radiat Oncol. 2018 Dec 12;15:38-41. doi: 10.1016/j.ctro.2018.12.001. eCollection 2019 Feb.

6.

Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention.

Shin WJ, Zabel BA, Pachynski RK.

Front Immunol. 2018 Nov 30;9:2772. doi: 10.3389/fimmu.2018.02772. eCollection 2018.

7.

Chemerin modulation of tumor growth: potential clinical applications in cancer.

Shin WJ, Pachynski RK.

Discov Med. 2018 Aug;26(141):31-37. Review.

8.

Treatment of Advanced Prostate Cancer.

Thomas TS, Pachynski RK.

Mo Med. 2018 Mar-Apr;115(2):156-161. Review.

9.

Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.

Xu L, Pachynski RK.

Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7. Review.

PMID:
30105573
10.

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model.

Pachynski RK, Scholz A, Monnier J, Butcher EC, Zabel BA.

J Vis Exp. 2015 Apr 13;(98). doi: 10.3791/52657.

11.

The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.

Pachynski RK, Zabel BA, Kohrt HE, Tejeda NM, Monnier J, Swanson CD, Holzer AK, Gentles AJ, Sperinde GV, Edalati A, Hadeiba HA, Alizadeh AA, Butcher EC.

J Exp Med. 2012 Jul 30;209(8):1427-35. doi: 10.1084/jem.20112124. Epub 2012 Jul 2.

12.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL.

Blood. 2011 Nov 3;118(18):4890-901. doi: 10.1182/blood-2011-02-338020. Epub 2011 Aug 9.

13.

Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.

Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, Marincola FM, Wang E, Young HA, Murphy PM, Hwu P.

Hum Gene Ther. 2002 Nov 1;13(16):1971-80.

PMID:
12427307
15.

Presentation of integrins on leukocyte microvilli: a role for the extracellular domain in determining membrane localization.

Abitorabi MA, Pachynski RK, Ferrando RE, Tidswell M, Erle DJ.

J Cell Biol. 1997 Oct 20;139(2):563-71.

Supplemental Content

Loading ...
Support Center